Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China.

Objectives: The purpose of this study was to determine the incidence of myositis-specific autoantibodies (MSAs) in a cohort of Chinese patients with idiopathic inflammatory myopathies (IIMs) and to examine their associations with clinical characteristics and long-term prognosis.

Methods: Adult patients with confirmed IIMs (n = 515) were studied using the EUROLINE Autoimmune Inflammatory Myopathies 16 Ag (IgG) commercial line blot test to detect MSAs/myositis-associated autoantibodies. We collected the laboratory data and clinical features.

Clinical significance of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis: a monocentric cross-sectional study.

Objectives: To determine the prevalence of anti-transcriptional intermediary factor 1-γ antibody (anti-TIF1-γ-Ab) and to explore its associations with clinical features in patients with dermatomyositis.

Methods: Sixteen kinds of myositis-specific/associated antibodies were examined in 141 dermatomyositis patients by western blotting. Clinical features and laboratory data were collected.

Association of anti-NXP2 antibody with clinical characteristics and outcomes in adult dermatomyositis: results from clinical applications based on a myositis-specific antibody.

Objectives: The aim was to study and compare the clinical manifestations, auxiliary examinations, and therapeutic responses in patients with different myositis-specific antibody (MSA) types.

Method: We retrospectively investigated the medical records of 143 hospitalized dermatomyositis patients, all of whom were tested for MSAs, and performed follow-up. Patients were divided into groups with and without anti-nuclear matrix protein 2 (NXP2) antibodies (17 vs 126 patients).